Katherine Sizov

Katherine Sizov is the current CEO of Strella Biotechnology. Prior to their current position, they were with YouthHack and the Wharton Zicklin Center for Business Ethics Research. Katherine also interned with The National Institutes of Health from June 2013 to August 2016 where they applied CRISPR/Cas9 gene editing techniques to human muscle fibroblasts with a COL6A1 G.p290 mutation to rescue wild type phenotype.

Katherine Sizov majored in molecular biology and chemistry at the University of Pennsylvania. Katherine also completed a minor in engineering entrepreneurship. After graduation, they worked as a research associate at a biotechnology company.

Some individuals on their team include Maria Yamburenko - Principal Molecular Biologist, Zuyang Liu - IoT Lead, and Luke Tiffany - PNW Account Manager.